EP
IONS icon

Essential Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Essential Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555 Hold
7
– – ﹤0.01% 2449
2026
Q1 		$526 Hold
7
– – ﹤0.01% 2424
2025
Q4 		$554 Hold
7
– – ﹤0.01% 2204
2025
Q3 		$458 Buy
+7
New +$342 ﹤0.01% 2226

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Essential Partners's IONS Position: Q2 2026 in Review

Essential Partners held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 7 shares worth $555. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Essential Partners first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Essential Partners held 7 shares of Ionis Pharmaceuticals worth $555 as of Q2 2026.
  • Essential Partners left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2449 holding.
  • Essential Partners first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.